Document:

Exhibit
10.37 

 

CONSULTING
AGREEMENT

Effective
Date: December 22, 2019

 

THIS
CONSULTING AGREEMENT (this “Agreement”) is entered into by and between Actinium Pharmaceuticals, Inc., a Delaware
corporation with a business address at Actinium Pharmaceuticals, Inc., having a place of business at 275 Madison Ave, 7th
Floor, New York, NY. 10016, (“API”). (the “Company”), and Nitya G. Ray, Ph.D. with a business
address at 14 Baybury Court, East Hanover, NJ 07936 (“Consultant”), as of the date set forth above.

 

WHEREAS,
the Company wishes to obtain the services of Consultant for certain purposes, and Consultant wishes to provide such services,
all subject to the terms and conditions of this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual covenants contained herein, the Company and Consultant hereby agree to be legally bound
as follows:

 

1.
Services. During the Term, Consultant
shall perform for the Company the consulting services described in Schedule 1 (the “Services”).

 

2.
Compensation.

 

2.1
Fees for Services. In connection with the Services, the Company shall pay Consultant $250 US dollars per hour for direct
project work and $125 US dollars per hour for travel time authorized by the Company.

 

2.2
Benefits. Consultant is not an employee of the Company and will not be entitled to participate in or receive any benefit
or right as a Company employee under any Company employee benefit and welfare plan, including, without limitation, employee insurance,
pension, savings and security plans as a result of his entering into this Agreement.

 

2.3
Expenses. The Company shall reimburse Consultant for all pre-approved, reasonable expenses that are actually incurred and
necessary for the performance of Services by Consultant. Consultant shall invoice the Company for such expenses, which invoice
shall include reasonable supporting documentation (such as receipts) verifying such expenses.

 

2.4
Taxes and Withholdings. All taxes relating to Consultant’s performance under this Agreement shall be the responsibility
of Consultant. In particular, Consultant shall be solely responsible for the payment of all federal, state and local taxes or
contributions imposed or required under unemployment insurance, social security and income tax laws that pertain to the compensation
paid or reimbursements provided to Consultant.

 

3.
Duties of Consultant.

 

3.1
Availability of Consultant. Consultant shall hold himself available to Services (a) during normal business hours, other
reasonable times and such other times as the parties may agree, (b) at the Company’s offices, places the Company may request
from time to time or such other places as the parties may agree.

 

     

     

    

 

3.2
Efforts of Consultant. Consultant shall perform Services conscientiously and in a professional manner, and devote his best
efforts and abilities thereto. Consultant shall observe all policies and procedures of the Company, and such other directives
as may be promulgated from time to time by the Company’s officers or board of directors.

 

3.3
No Conflicting Agreements. Consultant represents and warrants that Consultant is not a party to any existing agreement
that would prevent Consultant from entering into and performing its obligations under this Agreement in accordance with its terms.
Consultant shall not enter into any agreement that is in conflict with, or that would prohibit or impair the performance of, Consultant’s
obligations under this Agreement in accordance with its terms.

 

3.4
Independent Contractor. Consultant understands and agrees that he is acting solely as an independent contractor of the
Company in performing any of the Services and as such agrees that, at all times, Consultant is not an employee of the Company.
This Agreement shall not be construed as authority for Consultant to act as the Company’s agent or in any similar capacity,
nor to make commitments of any kind for the account of or on behalf of the Company, and Consultant shall not take any action suggesting
otherwise.

 

3.5
Intentionally left blank.

 

3.6
Modification. Consultant agrees that, should a court determine that any provision, term or condition set forth in Sections
7.3 or 7.5 are invalid or unenforceable, the court may alter or modify any such provision, term or condition in a manner so as
to protect the Company’s legitimate business interests.

 

3.7
Social Security Number. Consultant certifies that he will supply his correct Social Security Number or Employer Identification
Number (EIN) to the Company. Consultant acknowledges that the Company will rely upon the foregoing certification in filing certain
documents and instruments required by law in connection with this Agreement, including, without limitation, Form 1099 under the
Internal Revenue Code of 1986, as amended (or any successor form).

 

4.
Confidentiality.

 

4.1
Company Confidential Information. Consultant shall hold in strict confidence, and not use, except for the benefit of the
Company, and not disclose to any person or entity without written authorization of the CEO of the Company, any Confidential Information
(as defined below) of the Company. “Confidential Information” means any proprietary or confidential information,
technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, customer
lists and customers, markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering,
marketing, distribution and sales methods and systems, sales and profit figures, finances and other business information disclosed
to Consultant by or on behalf of the Company, either directly or indirectly, whether in writing, orally or by drawings or inspection
of documents or other tangible property; provided, that Confidential Information shall not include any of the foregoing
items to the extent they have become publicly known and made generally available through no act of Consultant.

 

    2

    

    

 

4.2
Third Party Information Held by Consultant. Consultant shall not improperly use or disclose to the Company or any of its
directors, officers, employees or agents, any confidential information of any current or former client or other person or entity
with whom Consultant has an agreement or duty to keep such information confidential, and Consultant shall not bring onto the premises
of the Company any such information in any medium unless consented to in writing by such client, person or entity.

 

4.3
Third Party Information Held by the Company. Consultant recognizes that the Company has received, and in the future may
receive, from third parties Confidential Information subject to a duty on the Company’s part to maintain the confidentiality
of such information and to use it only for certain limited purposes. Consultant shall hold all such information in strict confidence
and not disclose it to any person or entity or use it except as necessary in carrying out Services, consistent with the Company’s
agreement with such third party. For purposes of this Agreement, such third party information shall be deemed part of the Confidential
Information of the Company.

 

4.4
Required Disclosure of Confidential Information. If Consultant is required by law or court or governmental order to disclose
Confidential Information, Consultant shall give the Company prompt written notice of such requirement such that the Company shall
have the opportunity to apply for a protective order, injunction or for confidential treatment of such Confidential Information.

 

5.
Ownership of Results. 

 

5.1
Assignment of Inventions. Consultant shall promptly make full written disclosure to the Company, shall hold in trust for
the sole right and benefit of the Company, and hereby assigns, transfers and conveys to the Company, or its designee, all of Consultant’s
worldwide right, title and interest in and to any and all inventions, original works of authorship, findings, conclusions, data,
discoveries, developments, concepts, improvements, trade secrets, techniques, processes and know-how, whether or not patentable
or registrable under patent, copyright or similar laws, that Consultant may solely or jointly conceive, develop or reduce to practice,
or cause to be conceived, developed or reduced to practice, in the performance of the Services or that result, to any extent,
from use of the Company’s premises or property (collectively, the “Inventions”), including any and all
moral rights and intellectual property rights inherent therein and appurtenant thereto, including, but not limited to, all patent
rights, copyrights, trademarks, know-how and trade secrets and the rights to apply for the same (collectively, “Intellectual
Property Rights”). Consultant further acknowledges and agrees that all original works of authorship that are made by
Consultant (solely or jointly with others) in the performance of the Services (a “Work”) and that are protectable
by copyright are “works made for hire,” as that term is defined in the United States Copyright Act. However, to the
extent that any Work may not, by operation of any applicable law, be a work made for hire, Consultant hereby assigns, transfers
and conveys to the Company all of Consultant’s worldwide right, title and interest in and to such Work, including all Intellectual
Property Rights relating thereto.

 

    3

    

    

 

5.2
Further Assurances. Upon the request and at the expense of the Company, Consultant shall execute and deliver any and all
instruments and documents and take such other acts as may be necessary or desirable to document the assignment and transfer described
in Section 5.1 or to enable the Company to secure its rights in the Inventions, Works and Intellectual Property Rights relating
thereto in any and all jurisdictions, or to apply for, prosecute and enforce Intellectual Property Rights in any and all jurisdictions
with respect to any Inventions or Works, or to obtain any extension, validation, re-issue, continuance or renewal of any such
Intellectual Property Right. Without limiting the foregoing, Consultant shall disclose to the Company all pertinent information
and data with respect thereto and shall execute all applications, specifications, oaths and all other instruments which the Company
deems necessary in order to apply for and obtain such rights and in order to assign and convey to the Company the sole and exclusive
right, title and interest in and to such Inventions, Works and any Intellectual Property Rights relating thereto. If the Company
is unable for any other reason to secure Consultant’s signature to apply for or to pursue any application for any United
States or foreign patent, trademark, copyright or other registration covering Inventions or Works assigned to the Company hereunder,
then Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Consultant’s
agent and attorney in fact, to act for and in Consultant’s behalf and stead to execute and file any such applications and
to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or trademark, copyright or other
registrations thereon with the same legal force and effect as if executed by Consultant.

 

6.
Term and Termination.

 

Term.
The initial term of this Agreement shall begin on the Effective Date, which will be on December 22, 2018 and shall continue until
March 31, 2019 (the “Term”) unless earlier terminated pursuant to this Section 6. Notwithstanding the foregoing,
the Company and Consultant may agree to extend the Term of the Agreement for an additional three months until June 30, 2019 if
the transition has not been properly completed.

 

6.1
Termination by the Company. The Company and Consultant shall have the right to terminate this Agreement on 15 days prior
written notice to the other party.

 

6.2
Obligations. Upon termination, the Company shall have no obligation to pay Consultant any fees or expenses that accrued
subsequent to (a) a breach of Consultant’s obligations hereunder, (b) the failure of Consultant to perform the Services
as contemplated by this Agreement or (c) the commission of fraud upon the Company by Consultant.

 

6.3
Survival. The provisions of Sections 3.4, 3.5, 3.6 and Articles 4, 5, 6 and 7 shall survive the expiration or termination
of this Agreement. The expiration or termination of this Agreement shall not impair any right or obligation of any party accruing
prior to the effective date of such expiration or termination.

 

    4

    

    

 

7.
Miscellaneous.

 

7.1
Release of Claims. In consideration for the obligations of the Company set forth in this Agreement, Consultant, on behalf
of himself, and his respective heirs, executors, administrators and assigns (collectively, “Employee Releasors”),
as may be applicable, hereby fully and forever release the Company and its respective officers, directors, employees, agents,
investors, stockholders (each of such foregoing persons who were or are acting on behalf of or at the Company’s direction),
parent, subsidiary and affiliate companies, predecessor and successor companies and assigns, of and from any known or unknown
claim, duty, obligation or cause of action relating to any matters of any kind that any of the Employee Releasors may possess
arising from the employment relationship between Company and Consultant from the beginning of time up until and including the
date of this Agreement including, without limitation:

 

(a)
any and all claims relating to or arising from Consultant’s employment relationship with the Company and the termination
of those relationships, including, without limitation Consultant’s rights to salary and benefits except as provided herein;

 

(b)
any and all claims for wrongful discharge of employment; breach of contract, both express and implied; breach of a covenant of
good faith and fair dealing, both express and implied, negligent or intentional infliction of emotional distress; negligent or
intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; negligence;
and defamation;

 

(c)
any and all claims for violation of any federal, state or municipal statute, including, but not limited to, Title VII of the Civil
Rights Act of 1964, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, and the Americans with Disabilities
Act of 1990, the Older Workers Benefits Protection Act of 1990 (“OWBPA”), the Americans with Disabilities Act, the
Family and Medical Leave Act, the civil whistleblower protection provisions of the Sarbanes-Oxley Act of 2002 and all other federal,
state and local laws dealing with discrimination on any basis, including but not limited to sex, race, national origin, veteran
status, religion, disability and age. This Agreement also includes any claim of wrongful termination, based on any legal theory
including but not limited to contract and personal injury;

 

(d)
any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; and

 

(e)
any and all claims for attorneys’ fees and costs.

 

The
Company and Consultant agree that the release set forth in this Section 7.2 shall be and remain in effect in all respects as a
complete general release as to the matters released. This release does not extend to any payments or benefits receivable, or obligations
incurred or specified under this Agreement.

 

    5

    

    

 

7.2
Nonsolicitation. Consultant agrees that for three years he will not either directly or indirectly solicit, induce, recruit
or encourage any of the Company’s officers or employees to terminate their relationship with the Company, or attempt to
solicit, induce, recruit or encourage officers, employees or of the Company, either for his own benefit or for the benefit of
any other person or entity. Further, Consultant agrees that he will not use any confidential or proprietary information of the
Company to attempt to negatively influence any of the Company’s employees from remaining in the Company or to solicit or
influence or attempt to solicit or influence any employee either directly or indirectly, to join another Company, institution
or other entity in competition with the business of the Company. Consultant agrees that he will be able to earn a livelihood without
violating the restrictions set forth in this Section 7.3. Further, for a period of thirty six (36) months from the date of this
Agreement, he shall not attempt to negatively influence any of the Company’s client’s or customers from purchasing
Company products or services or to solicit or influence any client, customer or other person either directly or indirectly, to
direct his or its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition
with the business of the Company.

 

For
a period of thirty six (36) months from the date of this Agreement, without the prior written consent of the Company, Consultant
will not directly or indirectly (i) acquire or agree, offer, seek or propose to acquire, ownership (including, but not limited
to, beneficial ownership as defined in Rule 13d-3 under the Exchange Act of 1934, as amended (the “Exchange Act”) of
the assets or business or more than fifteen (15%) percent of the outstanding securities issued by the Company or any of its subsidiaries,
(ii) make, or in any way participate in, any “solicitation” of “proxies” (as such terms are defined under
Regulation 14A of the Exchange Act) to vote or seek to advise or influence in any matter whatsoever any person or entity with
respect to the voting securities of the Company or any to his subsidiaries; (iii) form, join or in any way participate in a “group”
(within the meaning of Section 13 (d)(3) of the Exchange Act) with respect to any voting securities of the Company or any of his
subsidiaries.

 

7.3
Non-Competition. During the term of this Agreement and for a period of three (3) years thereafter, Consultant shall not,
either directly or indirectly, engage (as principal, partner, employee, consultant, owner, independent contractor, advisor or
otherwise, with or without compensation) in any business that directly or indirectly is developing, or plans to develop, radioimmuotherapies
for cancer or any other therapy related to bone marrow transplant or other programs that the company is developing (“Competing
Business”). Notwithstanding the foregoing, this does not prevent Consultant from being engaged or employed with a business
that has a Competing Business as part of its business, so long as you are not engaged or involved in any way in the Competing
Business at such business or enterprise.

 

7.4
Notices. All notices and other communications required or permitted hereunder shall be in writing and deemed to have been
given when hand delivered, sent by facsimile or mailed by registered or certified mail or overnight courier with tracking capabilities,
as follows, or as a party may otherwise notify to the other in accordance with this Section 7 (provided that such notice of change
of address or recipient shall be deemed given only when received):

 

	If
    to the Company, to:	 	If to Consultant: 
	 	 	 
	ACTINIUM
    PHARMACEUTICALS, INC.	 	Nitya G. Ray, PhD
	275 Madison
    Ave, 7th Floor,	 	14 Baybury Court
	New York
    City, New York 10016	 	East Hanover, NJ 07936
	Attention:
    Principal Financial Officer	 	 

 

    6

    

    

 

7.5
Company Property; Return. Consultant shall not remove any Company property from the Company’s premises without prior
written authorization from the Company. Promptly upon the expiration or termination of this Agreement, and earlier if requested
by the Company at any time, Consultant shall deliver to the Company (and shall not keep in Consultant’s possession or deliver
to anyone else) all Confidential Information of the Company (including all embodiments thereof) and all software, documentation,
devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials,
equipment, other documents or property, or reproductions of any aforementioned items, or any other work product whatsoever, developed
by Consultant as part of or in connection with the Services or otherwise belonging to the Company.

 

7.6
Indemnification. Consultant shall indemnify the Company for all costs, fees (including reasonable attorney’s fees),
expenses, losses and other damages arising from (a) any injury to person or damage to property caused by Consultant and (b) any
breach of this Agreement by Consultant.

 

Company
shall indemnify the Consultant for all costs, fees (including reasonable attorney’s fees), expenses, losses and other damages
arising from (a) any injury to person or damage to property caused by Company and (b) any breach of this Agreement by Company.

 

7.7
Assignment; No Third Party Beneficiaries. The Company may assign this Agreement without the prior written consent of Consultant.
Consultant hereby acknowledges and agrees that the duties and responsibilities of Consultant hereunder are of a personal nature
and shall not be assignable or delegable in whole or in part by Consultant. All of the terms and provisions of this Agreement
shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, executors, administrators, legal
representatives, successors and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended to
confer on any person or entity other than the parties hereto or their respective successors and permitted assigns, any benefits,
rights or remedies.

 

7.8
Governing Law, Jurisdiction and Attorney Fees. This Agreement shall be governed by and interpreted in accordance with laws
of the state of New York without giving effect to any conflict of laws provisions. Each party consents to the jurisdiction and
venue of the state and federal courts, as applicable, located in the State of New York, Manhattan County.

 

7.9
Equitable Relief. Consultant agrees that the limitations on its ability to solicit the Company’s employees and customers
as set forth in Section 3.5 are reasonably necessary to protect the Company’s legitimate business interests. Consultant
acknowledges that such limitations will not constitute or cause it or the Principal any undue hardship. Consultant further agrees
that it would be impossible or inadequate to measure and calculate the Company’s damages from any breach of the covenants
set forth in Sections 3, 4 and 5 of this Agreement, and that a breach of such covenants could cause serious and irreparable injury
to the Company. Accordingly, the Company shall have available, in addition to any other right or remedy available to it, the right
to obtain an injunction from a court of competent jurisdiction restraining such a breach (or threatened breach) and to specific
performance of any such Section. Consultant further agrees that no bond or other security shall be required in obtaining such
equitable relief and Consultant hereby consents to the issuance of such injunction and to the ordering of specific performance.

 

    7

    

    

 

7.10
Entire Agreement, Amendment and Waiver. This Agreement (including the schedules hereto and any Work Orders) is the sole
agreement between Consultant and the Company with respect to the Services and it supersedes all prior agreements and understandings
with respect thereto, whether oral or written. No amendment, supplement or other modification to any provision of this Agreement
shall be binding unless in writing and signed by both Consultant and the Company. No waiver of any rights under this Agreement
shall be effective unless in writing signed by the party to be charged. A waiver of a breach or violation of any provision of
this Agreement will not constitute or be construed as a waiver of any subsequent breach or violation of that provision or as a
waiver of any breach or violation of any other provision of this Agreement.

 

7.11
Severability. If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated
to be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other provision or
application of this Agreement which can be given effect without the invalid or unenforceable provision or application and shall
not invalidate or render unenforceable such provision or application in any other jurisdiction.

 

7.12
Headings. The headings in this Agreement are intended solely for convenience or reference and shall be given no effect
in the construction or interpretation of this Agreement.

 

7.13
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original
as against any party whose signature appears thereon, but all of which together shall constitute but one and the same instrument.

 

[Signature
Page Follows]

 

    8

    

    

 

IN
WITNESS WHEREOF, the undersigned, intending to be legally bound, have duly executed this Agreement as of the Effective Date.

 

	

    ACTINIUM PHARMACEUTICALS, INC.	 	Nitya
    G. Ray, PhD
	 	 	 
	/s/
    Sandesh Seth 	 	/s/
    Nitya G. Ray
	Authorized
Signature	 	Authorized
    Signature
	 	 	 
	Name:
    Sandesh Seth	 	 
	Title:
    Chairman and CEO	 	 

   

This
Agreement is to be executed in duplicate.

Please
return one fully executed copy to the Company at the address above.Exhibit 10.38

 

ACTINIUM
PHARMACEUTICALS, INC. 

 

Common
Stock

(par value $0.001 per share)

 

Amended
and Restated At Market Issuance Sales Agreement

 

December
28, 2018

 

B.
Riley FBR, Inc.

299
Park Avenue, 7th Floor

New
York, NY 10017

 

JonesTrading
Institutional Services LLC

757
Third Avenue, 23rd Floor

New
York, NY 10017

 

Ladies
and Gentlemen:

 

Actinium
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and B. Riley FBR, Inc., as successor by merger
to FBR Capital Markets & Co., (“B. Riley FBR”) are parties to that certain At Market Issuance Sales Agreement
dated March 16, 2017 (the “Original Agreement”). Together with JonesTrading Institutional Services LLC (“JonesTrading”;
each of B. Riley FBR and JonesTrading individually an “Agent” and collectively, the “Agents”),
the Company and the Agents desire to amend and restate the Original Sales Agreement with this agreement (the “Agreement”),
and hereby agree as follows:

 

1. Issuance
and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and
subject to the conditions set forth herein, it may issue and sell through or to the Agents, as agent or principal, shares
(the “Placement Shares”) of the Company’s common stock, par value $0.001 per share (the
“Common Stock”), provided however, that in no event shall the Company issue or sell through the
Agents such number of Placement Shares that (a) exceeds the number of shares of Common Stock registered on the effective
Registration Statement (as defined below) pursuant to which the offering is being made, or (b) exceeds the number of
authorized but unissued shares of Common Stock (the lesser of (a) and (b), the “Maximum Amount”).
Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set
forth in this Section 1 on the number of Placement Shares issued and sold under this Agreement shall be the sole
responsibility of the Company and that the Agents shall have no obligation in connection with such compliance. The issuance
and sale of Placement Shares through the Agents will be effected pursuant to the Registration Statement (as defined below),
although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue any
Placement Shares.

  

     

    

    

 

The
Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations
thereunder (the “Securities Act”), with the Securities and Exchange Commission (the “Commission”),
a registration statement on Form S-3 (File No. 333-216748), including a base prospectus relating to certain securities, including
the Placement Shares to be issued from time to time by the Company, and which incorporates by reference documents that the Company
has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and
regulations thereunder (the “Exchange Act”). The Company has prepared a prospectus supplement to the base prospectus
included as part of such registration statement, specifically relating to the Placement Shares (the “Prospectus Supplement”).
The Company will furnish to the Agents, for use by the Agents, copies of the prospectus included as part of such registration
statement, as supplemented by the Prospectus Supplement, relating to the Placement Shares. Except where the context otherwise
requires, such registration statement, and any post-effective amendment thereto, including all documents filed as part thereof
or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently
filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement
pursuant to Rule 430B of the Securities Act, or any subsequent registration statement on Form S-3 filed pursuant to Rule 415(a)(6)
under the Securities Act by the Company to cover any Placement Shares, is herein called the “Registration Statement.”
The base prospectus, including all documents incorporated or deemed incorporated therein by reference to the extent such information
has not been superseded or modified in accordance with Rule 412 under the Securities Act (as qualified by Rule 430B(g) of the
Securities Act), included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in
which such prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to
Rule 424(b) under the Securities Act, is herein called the “Prospectus.” Any reference herein to the Registration
Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated
or deemed incorporated by reference therein, and any reference herein to the terms “amend,” “amendment”
or “supplement” with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include
the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein (the
“Incorporated Documents”).

 

For
purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto
shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and
Retrieval System, or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively,
“EDGAR”).

 

2. Placements.
Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a “Placement”), it
will notify an Agent (the “Designated Agent”) by email notice (or other method mutually agreed to in writing
by the Parties) of the number of Placement Shares, the time period during which sales are requested to be made, any limitation
on the number of Placement Shares that may be sold in any one day and any minimum price below which sales may not be made (a “Placement
Notice”), the form of which is attached hereto as Schedule 1. The Placement Notice shall originate from any of
the individuals from the Company set forth on Schedule 3 (with a copy to each of the other individuals from the Company
listed on such schedule), and shall be addressed to each of the individuals from the Designated Agent set forth on Schedule
3, as such Schedule 3 may be amended from time to time. Provided that the Company is otherwise in compliance with the
terms of this Agreement, the Placement Notice shall be effective immediately upon receipt by the Designated Agent unless and until
(i) the Designated Agent declines to accept the terms contained therein for any reason, in its sole discretion, (ii) the entire
amount of the Placement Shares thereunder has been sold, (iii) the Company suspends or terminates the Placement Notice or (iv)
this Agreement has been terminated under the provisions of Section 13. The amount of any discount, commission or other
compensation to be paid by the Company to the Designated Agent in connection with the sale of the Placement Shares shall be calculated
in accordance with the terms set forth in Schedule 2. It is expressly acknowledged and agreed that neither the Company
nor the Designated Agent will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until
the Company delivers a Placement Notice to the Designated Agent and the Designated Agent does not decline such Placement Notice
pursuant to the terms set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between
the terms of Sections 2 or 3 of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice
will control.

  

    2

    

    

 

3. Sale
of Placement Shares by the Agents. Subject to the terms and conditions of this Agreement, for the period specified in a Placement
Notice, the Designated Agent will use its commercially reasonable efforts consistent with its normal trading and sales practices
and applicable state and federal laws, rules and regulations and the rules of such national securities exchange that the Company’s
Common Stock is listed on (the “Exchange”), to sell the Placement Shares up to the amount specified in, and
otherwise in accordance with the terms of, such Placement Notice. The Designated Agent will provide written confirmation to the
Company no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has
made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the compensation payable
by the Company to the Designated Agent pursuant to Section 2 with respect to such sales, and the Net Proceeds (as defined
below) payable to the Company, with an itemization of the deductions made by the Designated Agent (as set forth in Section
5(b)) from the gross proceeds that it receives from such sales. Subject to the terms of a Placement Notice, the Designated
Agent may sell Placement Shares by any method permitted by law deemed to be an “at the market offering” as defined
in Rule 415 of the Securities Act. “Trading Day” means any day on which Common Stock is purchased and sold
on the Exchange.

 

4. Suspension
of Sales. The Company or the Designated Agent may, upon notice to the other party in writing (including by email correspondence
to each of the individuals of the other party set forth on Schedule 3, if receipt of such correspondence is actually acknowledged
by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable
facsimile transmission or email correspondence to each of the individuals of the other party set forth on Schedule 3),
suspend any sale of Placement Shares; provided, however, that such suspension shall not affect or impair any party’s
obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. While a suspension is in
effect, any obligation under Sections 7(l), 7(m), and 7(n) with respect to the delivery of certificates, opinions, or comfort
letters to the Agents, shall be waived; provided, however, that such waiver shall not apply for the Representation Date
(as defined below) occurring on the date that the Company files its annual report on Form 10-K. Each of the parties agrees that
no such notice under this Section 4 shall be effective against any other party unless it is made to one of the individuals
named on Schedule 3 hereto, as such Schedule may be amended from time to time.

  

    3

    

    

 

5. Sale
and Delivery to the Designated Agent; Settlement.

 

a. Sale
of Placement Shares. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, upon the Designated Agent’s acceptance of the terms of a Placement Notice, and unless the sale of the
Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this
Agreement, the Designated Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts
consistent with its normal trading and sales practices to sell such Placement Shares up to the amount specified in, and otherwise
in accordance with the terms of, such Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance
that the Designated Agent will be successful in selling Placement Shares, (ii) the Designated Agent will incur no liability or
obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure
by the Designated Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices and
applicable law and regulations to sell such Placement Shares as required under this Agreement and (iii) the Designated Agent shall
be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement, except as otherwise agreed
by the Designated Agent and the Company.

 

b. Settlement
of Placement Shares. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares
will occur on the second (2nd) Trading Day (or such earlier day as is industry practice for regular-way trading) following
the date on which such sales are made (each, a “Settlement Date”). The amount of proceeds to be delivered to
the Company on a Settlement Date against receipt of the Placement Shares sold (the “Net Proceeds”) will be
equal to the aggregate sales price received by the Designated Agent for the Placement Shares, after deduction for (i) the Designated
Agent’s commission, discount or other compensation for such sales payable by the Company pursuant to Section 2 hereof,
and (ii) any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.

 

c. Delivery
of Placement Shares. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically
transfer the Placement Shares being sold by crediting the Designated Agent’s or its designee’s account (provided the
Designated Agent shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement
Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery
as may be mutually agreed upon by the parties hereto which in all cases shall be freely tradable, transferable, registered shares
in good deliverable form. On each Settlement Date, the Designated Agent will deliver the related Net Proceeds in same day funds
to an account designated by the Company on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer
agent (if applicable), defaults in its obligation to deliver Placement Shares on a Settlement Date, through no fault of the Designated
Agent, the Company agrees that in addition to and in no way limiting the rights and obligations set forth in Section 11(a)
hereto, it will (i) hold the Designated Agent harmless against any loss, claim, damage, or reasonable, documented expense
(including reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such default
by the Company or its transfer agent (if applicable) and (ii) pay to the Designated Agent (without duplication) any commission,
discount, or other compensation to which it would otherwise have been entitled absent such default.

  

    4

    

    

 

d.
Limitations on Offering Size. Under no circumstances shall the Company cause or request the offer or sale of any Placement
Shares if, after giving effect to the sale of such Placement Shares, the aggregate number of Placement Shares sold pursuant to
this Agreement would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement, the Maximum Amount,
(B) the amount available for offer and sale under the currently effective Registration Statement and (C) the amount authorized
from time to time to be issued and sold under this Agreement by the Company’s board of directors, a duly authorized committee
thereof or a duly authorized executive committee, and notified to the Designated Agent in writing. Under no circumstances shall
the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum
price authorized from time to time by the Company’s board of directors, a duly authorized committee thereof or a duly authorized
executive committee, and notified to the Designated Agent in writing. Further, under no circumstances shall the Company cause
or permit the aggregate offering amount of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.

 

e. Sales
Through Agents. The Company agrees that any offer to sell, any solicitation of an offer to buy, or any sales of Common Stock
or any other equity security of the Company shall only be effected by or through an Agent, and only a single Agent, on any single
given date, and in no event shall the Company request that more than one Agent sell Securities on the same day; provided however
that (i) the foregoing limitation shall not apply to (A) exercise of any option, warrant, right or any conversion privilege set
forth in the instruction governing such securities, (B) sales solely to employees, directors or security holders of the Company
or its subsidiaries, or to a trustee or other person acquiring such securities for the accounts of such person and (ii) such limitation
shall not apply (A) on any day during which no sales are made pursuant to this Agreement or (B) during a period in which the Company
has notified the Agents that it will not sell Common Stock under this Agreement and (1) no Placement Notice is pending or (2)
after a Placement Notice has been withdrawn.

 

6. Representations
and Warranties of the Company. Except as disclosed in the Registration Statement or Prospectus (including the Incorporated
Documents), the Company represents and warrants to, and agrees with each Agent that as of the date of this Agreement and as of
each Applicable Time (as defined below), unless such representation, warranty or agreement specifies a different date or time:

 

a. Registration
Statement and Prospectus. The Company and, assuming no act or omission on the part of the Agents that would make such statement
untrue, the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of
Form S-3 under the Securities Act. The Registration Statement has been filed with the Commission and has been declared effective
under the Securities Act. The Prospectus will name B. Riley FBR and JonesTrading as the agents in the section entitled “Plan
of Distribution.” The Company has not received, and has no notice of, any order of the Commission preventing or suspending
the use of the Registration Statement, or threatening or instituting proceedings for that purpose. The Registration Statement
and the offer and sale of Placement Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and
comply in all material respects with said Rule. Any statutes, regulations, contracts or other documents that are required to be
described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement have been so
described or filed. Copies of the Registration Statement, the Prospectus, and any such amendments or supplements and all documents
incorporated by reference therein that were filed with the Commission on or prior to the date of this Agreement have been delivered,
or are available through EDGAR, to the Agents and their counsel. The Company has not distributed and, prior to the later to occur
of each Settlement Date and completion of the distribution of the Placement Shares, will not distribute any offering material
in connection with the offering or sale of the Placement Shares other than the Registration Statement and the Prospectus and any
Issuer Free Writing Prospectus (as defined below) to which the Agents have consented, such consent not to be unreasonably withheld,
conditioned or delayed. The Common Stock is currently listed on the Exchange. The Company has not, in the 12 months preceding
the date hereof, received notice from the Exchange to the effect that the Company is not in compliance in all material respects
with the listing or maintenance requirements of the Exchange. The Company has no reason to believe that it will not in the foreseeable
future continue to be in compliance with all such listing and maintenance requirements.

  

    5

    

    

 

b. No
Misstatement or Omission. The Registration Statement, when it became effective, and the Prospectus, and any amendment or supplement
thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects with the
requirements of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date, will
conform in all material respects with the requirements of the Securities Act. The Registration Statement, when it became or becomes
effective, did not, and will not, contain an untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading. The Prospectus and any amendment and supplement
thereto, on the date thereof and at each Applicable Time (defined below), did not or will not include an untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading. The documents incorporated by reference in the Prospectus or any Prospectus Supplement did not,
and any further documents filed and incorporated by reference therein will not, when filed with the Commission, contain an untrue
statement of a material fact or omit to state a material fact required to be stated in such document or necessary to make the
statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing shall not
apply to statements in, or omissions from, any such document made in reliance upon, and in conformity with, information furnished
to the Company by an Agent specifically for use in the preparation thereof.

 

c. Conformity
with Securities Act and Exchange Act. The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or any
amendment or supplement thereto, and the Incorporated Documents, when such documents were or are filed with the Commission under
the Securities Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed or
will conform in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.

  

    6

    

    

 

d. Financial
Information. The consolidated financial statements of the Company included or incorporated by reference in the Registration
Statement and the Prospectus, together with the related notes and schedules, present fairly, in all material respects, the consolidated
financial position of the Company and the Subsidiaries (as defined below) as of the dates indicated and the consolidated statement
of operations, consolidated statement of cash flows and consolidated statement of stockholders’ equity (deficit) of the
Company for the periods specified and have been prepared in compliance in all material respects with the requirements of the Securities
Act and Exchange Act, as applicable, and in conformity with generally accepted accounting principles (“GAAP”)
in the United States as in effect as of the time of filing applied on a consistent basis (except for such adjustments to accounting
standards and practices as are noted therein) during the periods involved (subject, in the case of unaudited financial statements,
to normal recurring adjustments and to the extent they may exclude footnotes or may be condensed or summarized statements); the
other financial and statistical data with respect to the Company and the Subsidiaries contained or incorporated by reference in
the Registration Statement and the Prospectus, are accurately and fairly presented and prepared on a basis consistent with the
financial statements and books and records of the Company; there are no financial statements (historical or pro forma) that are
required to be included or incorporated by reference in the Registration Statement, or the Prospectus that are not included or
incorporated by reference as required; the Company and the Subsidiaries do not have any material liabilities or obligations, direct
or contingent (including any off balance sheet obligations), not described in the Registration Statement, and the Prospectus which
are required to be described in the Registration Statement or Prospectus; and all disclosures contained or incorporated by reference
in the Registration Statement and the Prospectus, if any, regarding “non-GAAP financial measures” (as such term is
defined by the rules and regulations of the Commission) comply in all material respects with Regulation G of the Exchange Act
and Item 10 of Regulation S-K under the Securities Act, to the extent applicable.

 

e. Conformity
with EDGAR Filing. The Prospectus delivered to the Agents for use in connection with the sale of the Placement Shares pursuant
to this Agreement will be identical to the versions of the Prospectus created to be transmitted to the Commission for filing via
EDGAR, except to the extent permitted by Regulation S-T.

 

f. Organization.
The Company and any subsidiary that is a significant subsidiary (as such term is defined in Rule 1-02 of Regulation S-X promulgated
by the Commission) (each, a “Subsidiary”, collectively, the “Subsidiaries”), are, and will
be, duly organized, validly existing as a corporation and in good standing under the laws of their respective jurisdictions of
organization. The Company and the Subsidiaries are, and will be, duly licensed or qualified as a foreign corporation for transaction
of business and in good standing under the laws of each other jurisdiction in which their respective ownership or lease of property
or the conduct of their respective businesses requires such license or qualification, and have all corporate power and authority
necessary to own or hold their respective properties and to conduct their respective businesses as described in the Registration
Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority
would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a material
adverse effect on the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders’
equity or results of operations of the Company and the Subsidiaries taken as a whole, or prevent the consummation of the transactions
contemplated hereby (a “Material Adverse Effect”).

  

    7

    

    

 

g. Subsidiaries.
As of the date hereof, the Company’s only Subsidiaries are set forth on Schedule 6(g). The Company owns directly
or indirectly, all of the equity interests of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance,
right of first refusal or other restriction, and all the equity interests of the Subsidiaries are validly issued and are fully
paid, nonassessable and free of preemptive and similar rights.

 

h. No
Violation or Default. Neither the Company nor any Subsidiary is (i) in violation of its charter or by-laws or similar organizational
documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default,
in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan
agreement or other agreement or instrument to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary
is bound or to which any of the property or assets of the Company or any Subsidiary is subject; or (iii) in violation of any law
or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having
jurisdiction over the Company, except, in the case of each of clauses (ii) and (iii) above, for any such violation or default
that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the Company’s
knowledge, no other party under any material contract or other agreement to which it or any Subsidiary is a party is in default
in any respect thereunder where such default would reasonably be expected to have a Material Adverse Effect.

 

i. No
Material Adverse Effect. Since the date of the most recent financial statements of the Company included or incorporated by
reference in the Registration Statement and Prospectus, there has not been (other than those noted below in this paragraph) (i)
any Material Adverse Effect, or any development involving a prospective Material Adverse Effect, in or affecting the business,
properties, management, condition (financial or otherwise), results of operations, or prospects of the Company and the Subsidiaries
taken as a whole, (ii) any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii) any obligation
or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or the Subsidiaries,
which is material to the Company and the Subsidiaries taken as a whole, (iv) any material change in the capital stock (other than
(A) the grant of additional options or other awards under or outside the Company’s existing stock incentive plans, (B) changes
in the number of outstanding shares of Common Stock of the Company due to the issuance of shares upon the exercise or conversion
of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof, (C) as a result of the issuance
of Placement Shares, (D) any repurchases of capital stock of the Company, (E) as described in a proxy statement filed on Schedule
14A or a Registration Statement on Form S-4, or (F) otherwise publicly announced) or outstanding long-term indebtedness of the
Company or the Subsidiaries or (v) any dividend or distribution of any kind declared, paid or made on the capital stock of the
Company or any Subsidiary, other than in each case above (1) in the ordinary course of business. (2) as otherwise disclosed in
the Registration Statement or Prospectus or (3) where such matter, item, change, or development, individually or in the aggregate,
would not make the statements in the Registration Statement or the Prospectus contain an untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

  

    8

    

    

 

j. Capitalization.
The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and non-assessable
and, other than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights, rights
of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration
Statement and the Prospectus as of the dates referred to therein (other than (i) the grant of additional options or other awards
under the Company’s existing stock incentive plans, (ii) changes in the number of outstanding Common Stock of the Company
due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock
outstanding on the date hereof, (iii) as a result of the issuance of Placement Shares, or (iv) any repurchases of capital stock
of the Company) and such authorized capital stock conforms to the description thereof set forth in the Registration Statement
and the Prospectus. The description of the Common Stock in the Registration Statement and the Prospectus is complete and accurate
in all material respects. As of the date referred to therein, the Company did not have material outstanding any options to purchase,
or any rights or warrants to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts
or commitments to issue or sell, any shares of capital stock or other securities.

 

k. S-3
Eligibility. (i) At the time of filing the Registration Statement and (ii) at the time of the most recent amendment thereto
for the purposes of complying with Section 10(a)(3) of the Securities Act (whether such amendment was by post-effective amendment,
incorporated report filed pursuant to Section 13 or 15(d) of the Exchange Act or form of prospectus), the Company met the then
applicable requirements for use of Form S-3 under the Securities Act, including compliance with General Instruction I.B.1 of Form
S-3.

 

l. Authorization;
Enforceability. The Company has full legal right, power and authority to enter into this Agreement and perform the transactions
contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and
binding agreement of the Company enforceable against the Company in accordance with its terms, except to the extent that (i) enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally
and by general equitable principles and (ii) the indemnification and contribution provisions of Section 11 hereof may be
limited by federal or state securities laws and public policy considerations in respect thereof.

 

m. Authorization
of Placement Shares. The Placement Shares, when issued and delivered pursuant to the terms approved by the board of directors
of the Company or a duly authorized committee thereof, or a duly authorized executive officer, against payment therefor as provided
herein, will be duly and validly authorized and issued and fully paid and nonassessable, free and clear of any pledge, lien, encumbrance,
security interest or other claim (other than any pledge, lien, encumbrance, security interest or other claim arising from an act
or omission of an Agent or a purchaser), including any statutory or contractual preemptive rights, resale rights, rights of first
refusal or other similar rights, and will be registered pursuant to Section 12 of the Exchange Act. The Placement Shares, when
issued, will conform in all material respects to the description thereof set forth in or incorporated into the Prospectus.

  

    9

    

    

 

n. No
Consents Required. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator
or any governmental or regulatory authority having jurisdiction over the Company is required for the execution, delivery and performance
by the Company of this Agreement, and the issuance and sale by the Company of the Placement Shares as contemplated hereby, except
for the registration of the Placement Shares under the Securities Act and such consents, approvals, authorizations, orders and
registrations or qualifications as may be required under applicable state securities laws or by the by-laws and rules of the Financial
Industry Regulatory Authority (“FINRA”) or the Exchange, including any notices that may be required by Exchange,
in connection with the sale of the Placement Shares by the Agents.

 

o. No
Preferential Rights. (i) No person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities
Act (each, a “Person”), has the right, contractual or otherwise, to cause the Company to issue or sell to such
Person any Common Stock or shares of any other capital stock or other securities of the Company (other than upon the exercise
of options or warrants to purchase Common Stock or upon the exercise of options that may be granted, or issuances of Common Stock
or other equity awards, from time to time under or outside of the Company’s stock incentive plans), (ii) no Person has any
preemptive rights, rights of first refusal, or any other rights (whether pursuant to a “poison pill” provision or
otherwise) to purchase any Common Stock or shares of any other capital stock or other securities of the Company from the Company
which have not been duly waived with respect to the offering contemplated hereby, (iii) no Person has the right to act as an underwriter
or as a financial advisor to the Company in connection with the offer and sale of the Common Stock as contemplated by this Agreement,
and (iv) no Person has the right, contractual or otherwise, to require the Company to register under the Securities Act any Common
Stock or shares of any other capital stock or other securities of the Company, or to include any such shares or other securities
in the Registration Statement or the offering contemplated thereby, whether as a result of the filing or effectiveness of the
Registration Statement or the sale of the Placement Shares as contemplated thereby or otherwise, except for those shares and securities
currently subject to registration statements on file with the Commission.

 

p. Independent
Public Accountant. GBH CPAs, PC (the “Accountant”), whose report on the consolidated financial statements
of the Company is filed with the Commission as part of the Company’s most recent Annual Report on Form 10-K filed with the
Commission and incorporated into the Registration Statement, are and, during the periods covered by their report, were independent
public accountants within the meaning of the Securities Act and the Public Company Accounting Oversight Board (United States).
To the Company’s knowledge the Accountant is not in violation of the auditor independence requirements of the Sarbanes-Oxley
Act of 2002 (the “Sarbanes-Oxley Act”) with respect to the Company.

 

q. Enforceability
of Agreements. All agreements between the Company and third parties expressly referenced in the Prospectus, other than such
agreements that have expired by their terms or whose termination is disclosed in documents filed by the Company on EDGAR, are
legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the extent
that (i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’
rights generally and by general equitable principles and (ii) the indemnification provisions of certain agreements may be limited
by federal or state securities laws or public policy considerations in respect thereof, and except for any unenforceability that,
individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.

  

    10

    

    

 

r. No
Litigation. There are no legal, governmental or regulatory actions, suits or proceedings pending, nor, to the Company’s
knowledge, any legal, governmental or regulatory investigations, to which the Company or a Subsidiary is a party or to which any
property of the Company or any Subsidiary is the subject that, individually or in the aggregate, if determined adversely to the
Company or any Subsidiary, would reasonably be expected to have a Material Adverse Effect or materially and adversely affect the
ability of the Company to perform its obligations under this Agreement; to the Company’s knowledge, no such actions, suits
or proceedings are threatened by any governmental or regulatory authority or threatened by others that, individually or in the
aggregate, if determined adversely to the Company or any Subsidiary, would reasonably be expected to have a Material Adverse Effect;
and there are no current or pending legal, governmental or regulatory actions, suits or proceedings or, to the knowledge of the
Company, investigations that are required under the Securities Act to be described in the Prospectus that are not described in
the Prospectus including any Incorporated Document.

 

s. Licenses
and Permits. The Company and the Subsidiaries possess or have obtained, all licenses, certificates, consents, orders, approvals,
permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local
or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties
or the conduct of their respective businesses as described in the Registration Statement and the Prospectus (the “Permits”),
except where the failure to possess, obtain or make the same would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received written notice of any proceeding relating
to revocation or modification of any such Permit or has any reason to believe that such Permit will not be renewed in the ordinary
course, except where the revocation, modification or failure to obtain the renewal of any such Permit would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

t. No
Material Defaults. Neither the Company nor any Subsidiary has defaulted on any installment on indebtedness for borrowed money
or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, could reasonably be expected
to have a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since
the filing of its last Annual Report on Form 10-K, indicating that it (i) has failed to pay any dividend or sinking fund installment
on preferred stock or (ii) has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more
long-term leases, which defaults, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.

 

u. Certain
Market Activities. Neither the Company, nor any Subsidiary, nor to the Company’s knowledge any of their respective directors,
officers or controlling persons has taken, directly or indirectly, any action designed, or that has constituted or would reasonably
be expected to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of the Placement Shares.

  

    11

    

    

 

v. Broker/Dealer
Relationships. Neither the Company nor any Subsidiary or any related entities (i) is required to register as a “broker”
or “dealer” in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more
intermediaries, controls or is a “person associated with a member” or “associated person of a member”
(within the meaning set forth in the FINRA Manual).

 

w. No
Reliance. The Company has not relied upon the Agents or legal counsel for the Agents for any legal, tax or accounting advice
in connection with the offering and sale of the Placement Shares.

 

x. Taxes.
The Company and the Subsidiaries have filed all federal, state, local and foreign tax returns which have been required to
be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being
contested in good faith, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect.
Except as otherwise disclosed in or contemplated by the Registration Statement or the Prospectus, no tax deficiency has been determined
adversely to the Company or any Subsidiary which has had, or would reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or
assessment which has been asserted or threatened against it which could have a Material Adverse Effect.

 

y. Title
to Real and Personal Property. The Company and the Subsidiaries have good and valid title in fee simple to all items of real
property and good and valid title to all personal property (excluding Intellectual Property which is addressed below) described
in the Registration Statement or Prospectus as being owned by them that are material to the businesses of the Company or such
Subsidiary, in each case free and clear of all liens, encumbrances and claims, except those that (i) do not materially interfere
with the use made and proposed to be made of such property by the Company and the Subsidiaries or (ii) would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect. Any real property described in the Registration
Statement or Prospectus as being leased by the Company and the Subsidiaries is held by them under valid, existing and enforceable
leases, except those that (A) do not materially interfere with the use made or proposed to be made of such property by the Company
or the Subsidiaries or (B) would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect.

 

z. Intellectual
Property. To the Company’s knowledge, the Company and the Subsidiaries own or possess adequate enforceable rights to
use all patents, patent applications, trademarks (both registered and unregistered), service marks, trade names, trademark registrations,
service mark registrations, copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures) (collectively, the “Intellectual Property”),
necessary for the conduct of their respective businesses as conducted as of the date hereof, except to the extent that the
failure to own or possess adequate rights to use such Intellectual Property would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect; the Company and the Subsidiaries have not received any written notice of any claim
of infringement or conflict which asserted Intellectual Property rights of others, which infringement or conflict, if the subject
of an unfavorable decision, would reasonably be expected to result in a Material Adverse Effect; there are no pending, or to the
Company’s knowledge, threatened judicial proceedings or interference proceedings against the Company or its Subsidiaries
challenging the Company’s or any of its Subsidiary’s rights in or to or the validity of the scope of any of the Company’s
or any Subsidiary’s patents, patent applications or proprietary information, except for such right or claim that would not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; to the Company’s knowledge
no other entity or individual has any right or claim in any of the Company’s or any of its Subsidiary’s patents, patent
applications or any patent to be issued therefrom by virtue of any contract, license or other agreement entered into between such
entity or individual and the Company or any Subsidiary or by any non-contractual obligation, other than by written licenses granted
by the Company or any Subsidiary, except for such right or claim that would not, individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect; the Company and the Subsidiaries have not received any written notice of any
claim challenging the rights of the Company or its Subsidiaries in or to any Intellectual Property owned, licensed or optioned
by the Company or any Subsidiary which claim, if the subject of an unfavorable decision would result in a Material Adverse Effect.

  

    12

    

    

 

aa. Environmental
Laws. The Company and the Subsidiaries (i) are in compliance in all material respects with any and all applicable federal,
state, local and foreign laws, rules, regulations, decisions and orders relating to the protection of human health and safety,
the environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental
Laws”); (ii) have received and are in compliance in all material respects with all permits, licenses or other approvals
required of them under applicable Environmental Laws to conduct their respective businesses as described in the Registration Statement
and the Prospectus; and (iii) have not received notice of any actual or potential liability for the investigation or remediation
of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case of any
of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits, licenses, other approvals
or liability as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

bb. Disclosure
Controls. The Company maintains systems of internal accounting controls designed to provide reasonable assurance that (i)
transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)
access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect
to any differences. The Company is not aware of any material weaknesses in its internal control over financial reporting (other
than as set forth in the Registration Statement or the Prospectus). Since the date of the latest audited financial statements
of the Company included in the Prospectus, there has been no change in the Company’s internal control over financial reporting
that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial
reporting (other than as set forth in the Registration Statement or the Prospectus). The Company has established disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company and designed such disclosure controls and
procedures to ensure that material information relating to the Company and the Subsidiaries is made known to the certifying officers
by others within those entities, particularly during the period in which the Company’s Annual Report on Form 10-K or Quarterly
Report on Form 10-Q, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness
of the Company’s controls and procedures as of a date within 90 days prior to the filing date of the Form 10-K for the fiscal
year most recently ended (such date, the “Evaluation Date”). The Company presented in its Form 10-K for the
fiscal year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the most recent Evaluation Date. Since the most recent Evaluation Date, there
have been no significant changes in the Company’s internal controls (as such term is defined in Item 307(b) of Regulation
S-K under the Securities Act) or, to the Company’s knowledge, in other factors that could significantly adversely affect
the Company’s internal controls.

  

    13

    

    

 

cc. Sarbanes-Oxley
Act. There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company’s
directors or officers, in their capacities as such, to comply with any applicable provisions of the Sarbanes-Oxley Act and the
rules and regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer of the
Company (or each former principal executive officer of the Company and each former principal financial officer of the Company
as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports,
schedules, forms, statements and other documents required to be filed by it or furnished by it to the Commission during the past
12 months. For purposes of the preceding sentence, “principal executive officer” and “principal financial officer”
shall have the meanings given to such terms in the Exchange Act Rules 13a-15 and 15d-15.

   

dd. Finder’s
Fees. Neither the Company nor any Subsidiary has incurred any liability for any finder’s fees, brokerage commissions
or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to the
Agents pursuant to this Agreement.

 

ee. Labor
Disputes. No labor disturbance by or dispute with employees of the Company or any Subsidiary exists or, to the knowledge of
the Company, is threatened which would reasonably be expected to result in a Material Adverse Effect.

 

ff. Investment
Company Act. Neither the Company nor any Subsidiary is or, after giving effect to the offering and sale of the Placement Shares,
will be an “investment company” or an entity “controlled” by an “investment company,” as such
terms are defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”).

 

gg. Operations.
The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance in all material
respects with applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or the Subsidiaries are subject,
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced
by any governmental agency (collectively, the “Money Laundering Laws”), except as would not reasonably be expected
to result in a Material Adverse Effect; and no action, suit or proceeding by or before any court or governmental agency having
jurisdiction over the Company, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the
Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

  

    14

    

    

 

hh. Off-Balance
Sheet Arrangements. There are no transactions, arrangements and other relationships between and/or among the Company, and/or,
to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to, any structured
finance, special purpose or limited purpose entity (each, an “Off Balance Sheet Transaction”) that could reasonably
be expected to affect materially the Company’s liquidity or the availability of or requirements for its capital resources,
including those Off Balance Sheet Transactions described in the Commission’s Statement about Management’s Discussion
and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61), required to be described
in the Registration Statement or the Prospectus which have not been described as required.

 

ii. Underwriter
Agreements. The Company is not a party to any agreement with an agent or underwriter for any other “at the market”
or continuous equity transaction.

 

jj. ERISA.
To the knowledge of the Company, (i) each material employee benefit plan, within the meaning of Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended (“ERISA”), that is maintained, administered or contributed
to by the Company or any of its affiliates for employees or former employees of the Company and the Subsidiaries has been maintained
in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including
but not limited to ERISA and the Internal Revenue Code of 1986, as amended (the “Code”); (ii) no prohibited
transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result in a material
liability to the Company with respect to any such plan excluding transactions effected pursuant to a statutory or administrative
exemption; (iii) and for each such plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA,
no “accumulated funding deficiency” as defined in Section 412 of the Code has been incurred, whether or not waived,
and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) equals
or exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions other than,
in the case of (i), (ii) and (iii) above, as would not reasonably be expected to have a Material Adverse Effect.

 

kk. Forward-Looking
Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) (a “Forward-Looking Statement”) contained in the Registration Statement and the Prospectus has been made
or reaffirmed without a reasonable basis or has been disclosed other than in good faith. The Forward-Looking Statements incorporated
by reference in the Registration Statement and the Prospectus from the Company’s Annual Report on Form 10-K for the fiscal
year most recently ended (i) except for any Forward-Looking Statement included in any financial statements and notes thereto,
are within the coverage of the safe harbor for forward looking statements set forth in Section 27A of the Securities Act, Rule
175(b) under the Securities Act or Rule 3b-6 under the Exchange Act, as applicable, (ii) were made by the Company with a reasonable
basis and in good faith and reflect the Company’s good faith commercially reasonable best estimate of the matters described
therein as of the respective dates on which such statements were made, and (iii) have been prepared in accordance with Item 10
of Regulation S-K under the Securities Act.

  

    15

    

    

 

ll. Margin
Rules. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the
Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors
of the Federal Reserve System.

 

mm. Insurance.
The Company and the Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as the Company
and the Subsidiaries reasonably believe are adequate for the conduct of their business and as is customary for companies of similar
size engaged in similar businesses in similar industries.

 

nn. No
Improper Practices. (i) Neither the Company nor, to the Company’s knowledge, the Subsidiaries, nor to the Company’s
knowledge, any of their respective executive officers has, in the past five years, made any unlawful contributions to any candidate
for any political office (or failed fully to disclose any contribution in violation of law) or made any contribution or other
payment to any official of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar
public or quasi-public duty in violation of any law or of the character required to be disclosed in the Prospectus; (ii) to the
Company’s knowledge no relationship, direct or indirect, exists between or among the Company or, to the Company’s
knowledge, the Subsidiaries or any affiliate of any of them, on the one hand, and the directors, officers and stockholders of
the Company or, the Subsidiaries, on the other hand, that is required by the Securities Act to be described in the Registration
Statement and the Prospectus that is not so described; (iii) to the Company’s knowledge no relationship, direct or indirect,
exists between or among the Company or the Subsidiaries or any affiliate of them, on the one hand, and the directors, officers,
stockholders or directors of the Company or, the Subsidiaries, on the other hand, that is required by the rules of FINRA to be
described in the Registration Statement and the Prospectus that is not so described; (iv) there are no material outstanding loans
or advances or material guarantees of indebtedness by the Company or, to the Company’s knowledge, the Subsidiaries to or
for the benefit of any of their respective officers or directors or any of the members of the families of any of them; and (v)
to the Company’s knowledge the Company has not offered, or caused any placement agent to offer, Common Stock to any person
with the intent to influence unlawfully (A) a customer or supplier of the Company or the Subsidiaries to alter the customer’s
or supplier’s level or type of business with the Company or the Subsidiaries or (B) a trade journalist or publication to
write or publish favorable information about the Company or the Subsidiaries or any of their respective products or services,
and, (vi) neither the Company nor the Subsidiaries nor, to the Company’s knowledge, any employee or agent of the Company
or the Subsidiaries has made any payment of funds of the Company or the Subsidiaries or received or retained any funds in violation
of any law, rule or regulation (including, without limitation, the Foreign Corrupt Practices Act of 1977), which payment, receipt
or retention of funds is of a character required to be disclosed in the Registration Statement or the Prospectus.

  

oo. [Reserved]

  

    16

    

    

 

pp. No
Misstatement or Omission in an Issuer Free Writing Prospectus. Each Issuer Free Writing Prospectus, as of its issue date and
as of each Applicable Time (as defined in Section 25 below), did not, does not and will not include any information that
conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including
any incorporated document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not
apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information
furnished to the Company by an Agent specifically for use therein.

 

qq. No
Conflicts. Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares, nor the consummation
of any of the transactions contemplated herein and therein, nor the compliance by the Company with the terms and provisions hereof
and thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will
constitute a default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance
upon any property or assets of the Company pursuant to the terms of any contract or other agreement to which the Company is a
party or to which any of the property or assets of the Company is subject, except (i) such conflicts, breaches or defaults as
may have been waived and (ii) such conflicts, breaches and defaults that would not reasonably be expected to have a Material Adverse
Effect; nor will such action result (x) in any violation of the provisions of the organizational or governing documents of the
Company, or (y) in any material violation of the provisions of any statute or any order, rule or regulation applicable to the
Company or of any court or of any federal, state or other regulatory authority or other government body having jurisdiction over
the Company, except where such violation would not reasonably be expected to have a Material Adverse Effect.

 

rr. Compliance
with Applicable Laws. The Company and the Subsidiaries: (A) are and at all times have been in compliance with all statutes,
rules and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured
or distributed by the Company or the Subsidiaries (“Applicable Laws”) except where the failure to be so in
compliance would not reasonably be expected to result in a Material Adverse Effect, (b) have not received any Form 483 from the
FDA, notice of adverse finding, warning letter, or other written correspondence or notice from the FDA, the European Medicines
Agency (the “EMA”), or any other federal, state, local or foreign governmental or regulatory authority alleging
or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations,
permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which
would, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; (C) possess all material
Authorizations for the Company’s current state of product development as disclosed in the Registration Statement, and such
Authorizations are valid and in full force and effect and neither the Company nor the Subsidiaries is in material violation of
any term of any such Authorizations; (D) have not received written notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from the FDA, the EMA, or any other federal, state, local or foreign governmental or
regulatory authority or third party alleging that any Company product, operation or activity is in material violation of any Applicable
Laws or Authorizations and has no knowledge that the FDA, the EMA, or any other federal, state, local or foreign governmental
or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or
proceeding against the Company; (E) have not received notice that the FDA, EMA, or any other federal, state, local or foreign
governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material
Authorizations and has no knowledge that the FDA, EMA, or any other federal, state, local or foreign governmental or regulatory
authority is considering such action; and (F) have filed, obtained, maintained or submitted all reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations
for the Company’s current state of product development as disclosed in the registration Statement, except where the failure
to file such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments would
not result in a Material Adverse Effect, and that all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented
by a subsequent submission).

  

    17

    

    

 

ss. Clinical
Studies. All animal and other preclinical studies and clinical trials conducted by the Company or to the Company’s knowledge
on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects
in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by
qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to
those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained
in the Registration Statement and the Prospectus are accurate in all material respects, and, except as set forth in the Registration
Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of
which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration
Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received
any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the
termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described
in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the
Prospectus.

 

tt. Compliance
Program. The Company has taken such steps as the Company, believes are reasonable and appropriate to comply in all material
respects with applicable regulatory guidelines (including, without limitation, those administered by the FDA, the EMA, and any
other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by
the FDA or EMA); except where such noncompliance would not reasonably be expected to have a Material Adverse Effect.

   

    18

    

    

 

uu. OFAC.

 

(i) The
Company represents that, neither the Company nor any Subsidiary (collectively, the “Entity”) or to the Company’s
knowledge any director, officer, employee, agent, affiliate or representative of the Entity, is a government, individual, or entity
(in this paragraph (ss), “Person”) that is, or is owned or controlled by a Person that is:

 

(a) the
subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control
(“OFAC”), the United Nations Security Council (“UNSC”), the European Union (“EU”),
Her Majesty’s Treasury (“HMT”), or other relevant sanctions authority (collectively, “Sanctions”),
nor

 

(b) located,
organized or resident in a country or territory that is the subject of Sanctions.

 

(ii)
The Company represents and covenants that it will not, directly or indirectly, knowingly use the proceeds of the offering, or
knowingly lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other Person:

 

(a) to
fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding
or facilitation, is the subject of Sanctions; or

 

(b) in
any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering,
whether as underwriter, advisor, investor or otherwise).

 

(iii)
The Company represents and covenants that, except as detailed in the Prospectus, for the past 5 years, it has not knowingly engaged
in, is not now knowingly engaged in, and will not knowingly engage in, any dealings or transactions with any Person, or in any
country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.

 

vv. Stock
Transfer Taxes. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required to
be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully
paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with by the Company.

 

Any
certificate in the form of Exhibit 7(l) signed by an officer of the Company and delivered to the Agents or to counsel for the
Agents pursuant to or in connection with this Agreement shall be deemed to be a representation and warranty by the Company, as
applicable, to the Agents as to the matters set forth therein.

  

    19

    

    

 

7. Covenants
of the Company. The Company covenants and agrees with the Agents that:

 

a. Registration
Statement Amendments. After the date of this Agreement and during any period in which a prospectus relating to any Placement
Shares is required to be delivered by the Agents under the Securities Act (including in circumstances where such requirement may
be satisfied pursuant to Rule 172 under the Securities Act) (the “Prospectus Delivery Period”) (i) the Company
will notify the Agents promptly of the time when any subsequent amendment to the Registration Statement, other than documents
incorporated by reference or amendments not related to any Placement, has been filed with the Commission and/or has become effective
or any subsequent supplement to the Prospectus, other than documents incorporated by reference, has been filed and of any request
by the Commission for any amendment or supplement to the Registration Statement or Prospectus related to the Placement or for
additional information related to the Placement, (ii) the Company will prepare and file with the Commission, promptly upon any
Agent’s request, any amendments or supplements to the Registration Statement or Prospectus that, in such Agent’s reasonable
opinion, may be necessary or advisable in connection with the distribution of the Placement Shares by the Agents (provided,
however, that the failure of the Agents to make such request shall not relieve the Company of any obligation or liability
hereunder, or affect the Agents’ right to rely on the representations and warranties made by the Company in this Agreement
and provided, further, that the only remedy the Agents shall have with respect to the failure to make such filing shall be to
cease making sales under this Agreement until such amendment or supplement is filed); and (iii) the Company will cause each amendment
or supplement to the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b)
of the Securities Act or, in the case of any document to be incorporated therein by reference, to be filed with the Commission
as required pursuant to the Exchange Act, within the time period prescribed (the determination to file or not file any amendment
or supplement with the Commission under this Section 7(a), based on the Company’s reasonable opinion or reasonable
objections, shall be made exclusively by the Company). Notwithstanding the foregoing, the Company will not file any amendment
or supplement to the Registration Statement or Prospectus, other than documents incorporated by reference, relating to the Placement
Shares or a security convertible into the Placement Shares unless a copy thereof has been submitted to the Agents within a reasonable
period of time before the filing and the Agents have not reasonably and in good faith objected thereto (provided, however,
that (A) the failure of the Agents to make such objection shall not relieve the Company of any obligation or liability hereunder,
or affect the Agents’ right to rely on the representations and warranties made by the Company in this Agreement and (B)
the Company has no obligation to provide the Agents any advance copy of such filing or to provide the Agents an opportunity to
object to such filing if the filing does not name the Agents or does not relate to the transaction herein provided; and provided,
further, that the only remedy the Agents shall have with respect to the failure by the Company to obtain such consent shall be
to cease making sales under this Agreement) and the Company will furnish to the Agents at the time of filing thereof a copy of
any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except
for those documents available via EDGAR.

 

b. Notice
of Commission Stop Orders. The Company will advise the Agents, promptly after it receives notice or obtains knowledge thereof,
of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement,
of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation
or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent
the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the
Agents promptly after it receives any request by the Commission for any amendments to the Registration Statement or any amendment
or supplements to the Prospectus or any Issuer Free Writing Prospectus or for additional information related to the offering of
the Placement Shares or for additional information related to the Registration Statement, the Prospectus or any Issuer Free Writing
Prospectus.

  

    20

    

    

 

c. Delivery
of Prospectus; Subsequent Changes. During the Prospectus Delivery Period, the Company will use its commercially reasonably
efforts to comply in all material respects with all requirements imposed upon it by the Securities Act, as from time to time in
force, and to file on or before their respective due dates all reports and any definitive proxy or information statements required
to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under
the Exchange Act. If the Company has omitted any information from the Registration Statement pursuant to Rule 430A under the Securities
Act, it will use its commercially reasonable efforts to comply with the provisions of and make all requisite filings with the
Commission pursuant to said Rule 430A and to notify the Agents promptly of all such filings. If during the Prospectus Delivery
Period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
then existing, not misleading, or if during such Prospectus Delivery Period it is necessary to amend or supplement the Registration
Statement or Prospectus to comply with the Securities Act, the Company will promptly notify the Designated Agent to suspend the
offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement or
Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance; provided,
however, that the Company may delay the filing of any amendment or supplement, if in the judgment of the Company, it is in
the best interest of the Company.

 

d. Listing
of Placement Shares. During the Prospectus Delivery Period, the Company will use its commercially reasonable efforts to cause
the Placement Shares to be listed on the Exchange and to qualify the Placement Shares for sale under the securities laws of such
jurisdictions in the United States as the Agents reasonably designates and to continue such qualifications in effect so long as
required for the distribution of the Placement Shares; provided, however, that the Company shall not be required in connection
therewith to qualify as a foreign corporation or dealer in securities or file a general consent to service of process in any jurisdiction.

 

e. Delivery
of Registration Statement and Prospectus. The Company will furnish to the Agents and their counsel (at the reasonable expense
of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein)
and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during the Prospectus
Delivery Period (including all documents filed with the Commission during such period that are deemed to be incorporated by reference
therein), in each case as soon as reasonably practicable and in such quantities as the Agents may from time to time reasonably
request and, at the Agents’ request, will also furnish copies of the Prospectus to each exchange or market on which sales
of the Placement Shares may be made; provided, however, that the Company shall not be required to furnish any document
(other than the Prospectus) to the Agents to the extent such document is available on EDGAR.

 

f. Earnings
Statement. The Company will make generally available to its shareholders as soon as practicable, but in any event not later
than 15 months after the end of the Company’s current fiscal year-end, an earnings statement covering a 12-month period
that satisfies the provisions of Section 11(a) and Rule 158 of the Securities Act.

  

    21

    

    

 

g. Use
of Proceeds. The Company will use the Net Proceeds as described in the Prospectus in the section entitled “Use of Proceeds.”

 

h. Notice
of Other Sales. Without the prior written consent of the Agents, the Company will not, directly or indirectly, offer to sell,
sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered
pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase
or acquire, Common Stock during the period beginning on the date on which any Placement Notice is delivered to the Agents hereunder
and ending on the third (3rd) Trading Day immediately following the final Settlement Date with respect to Placement Shares sold
pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement
Shares covered by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly in any
other “at the market” or continuous equity transaction offer to sell, sell, contract to sell, grant any option to
sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities
convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire, Common Stock prior to the termination
of this Agreement; provided, however, that such restrictions will not be required in connection with the Company’s
issuance or sale of (i) Common Stock, options to purchase Common Stock or Common Stock issuable upon the exercise of options or
other equity awards, pursuant to any employee or director stock incentive or benefits plan or agreement, stock ownership plan
or dividend reinvestment plan (but not Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment plan)
of the Company whether now in effect or hereafter implemented; (ii) Common Stock issuable upon conversion of securities or the
exercise of warrants, options or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR
or otherwise in writing to the Agents, and (iii) Common Stock, or securities convertible into or exercisable for Common Stock,
offered and sold in a privately negotiated transaction to vendors, customers, strategic partners or potential strategic partners
or other investors conducted in a manner so as not to be integrated with the offering of Common Stock hereby.

 

i. Change
of Circumstances. The Company will, at any time during the pendency of a Placement Notice advise the Agents promptly after
it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material
respect any opinion, certificate, letter or other document required to be provided to the Agents pursuant to this Agreement.

 

j. Due
Diligence Cooperation. During the term of this Agreement, the Company will cooperate with any reasonable due diligence review
conducted by the Agents or their representatives in connection with the transactions contemplated hereby, including, without limitation,
providing information and making available documents and senior corporate officers, during regular business hours and at the Company’s
principal offices, as the Agents may reasonably request.

  

    22

    

    

 

k. Required
Filings Relating to Placement of Placement Shares. The Company agrees that on such dates as the Securities Act shall require,
the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the
Securities Act (each and every filing under Rule 424(b), a “Filing Date”), which prospectus supplement will
set forth, within the relevant period, the amount of Placement Shares sold through the Agents, the Net Proceeds to the Company
and the compensation payable by the Company to the Agents with respect to such Placement Shares or, if any such prospectus supplement
is not filed pursuant to Rule 424(b), otherwise include such information in the Company’s Exchange Act filings on such date
as shall be required, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on
which such sales were effected as may be required by the rules or regulations of such exchange or market.

 

l. Representation
Dates; Certificate. Each time during the term of this Agreement that the Company:

 

(i) amends
or supplements (other than a prospectus supplement relating solely to an offering of securities other than the Placement Shares)
the Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker,
or supplement but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus relating
to the Placement Shares;

 

(ii) files
an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a
material amendment to the previously filed Form 10-K);

 

(iii) files
its quarterly reports on Form 10-Q under the Exchange Act; or

 

(iv) files
a current report on Form 8-K containing amended financial information (other than information “furnished” pursuant
to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification
of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under
the Exchange Act;

 

(Each
date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a “Representation Date.”)

 

the
Company shall furnish the Agents (but in the case of clause (iv) above only if any Agent reasonably determines that the information
contained in such Form 8-K is material) with a certificate, in the form attached hereto as Exhibit 7(1). The requirement
to provide a certificate under this Section 7(1) shall be waived for any Representation Date occurring at a time at which
no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement
Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation
Date on which the Company files its annual report on Form 10-K. Notwithstanding the foregoing, (i) upon the delivery of the first
Placement Notice hereunder and (ii) if the Company subsequently decides to sell Placement Shares following a Representation Date
when the Company relied on such waiver and did not provide the Agents with a certificate under this Section 7(1), then
before the Agents sell any Placement Shares, the Company shall provide the Agents with a certificate, in the form attached hereto
as Exhibit 7(1), dated the date of the Placement Notice.

  

    23

    

    

 

m. Legal
Opinion. On or prior to the date of the first Placement Notice given hereunder the Company shall cause to be furnished to
the Agents written opinions and a negative assurance letter of The Matt Law Firm, PLLC (“Company Counsel”),
or other counsel reasonably satisfactory to the Agents, in the form attached hereto as Exhibit 7(m)(1) and 7(m)(2), respectively.
Thereafter, within five (5) Trading Days of each Representation Date with respect to which the Company is obligated to deliver
a certificate in the form attached hereto as Exhibit 7(l) for which no waiver is applicable, the Company shall cause to be furnished
to the Agents a written letter of Company Counsel in the form attached hereto as Exhibit 7(m)(2), modified, as necessary, to relate
to the Registration Statement and the Prospectus as then amended or supplemented; provided that, in lieu of such negative
assurance for subsequent periodic filings under the Exchange Act, counsel may furnish the Agents with a letter (a “Reliance
Letter”) to the effect that the Agents may rely on the negative assurance letter previously delivered under this Section
7(m) to the same extent as if it were dated the date of such letter (except that statements in such prior letter shall be deemed
to relate to the Registration Statement and the Prospectus as amended or supplemented as of the date of the Reliance Letter).

 

n. Comfort
Letter. On or prior to the date of the first Placement Notice given hereunder and within five (5) Trading Days after each
subsequent Representation Date, other than pursuant to Section 7(l)(iii), the Company shall cause its independent accountants
to furnish the Agents letters (the “Comfort Letters”), dated the date the Comfort Letter is delivered, which
shall meet the requirements set forth in this Section 7(n); provided, that if requested by an Agent, the Company shall
cause a Comfort Letter to be furnished to the Agents within ten (10) Trading Days of such request following the date of occurrence
of any restatement of the Company’s financial statements. The Comfort Letter from the Company’s independent accountants
shall be in a form and substance reasonably satisfactory to the Agents, (i) confirming that they are an independent public accounting
firm within the meaning of the Securities Act and the PCAOB, (ii) stating, as of such date, the conclusions and findings of such
firm with respect to the financial information and other matters ordinarily covered by accountants’ “comfort letters”
to underwriters in connection with registered public offerings (the first such letter, the “Initial Comfort Letter”)
and (iii) updating the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter
had it been given on such date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended
and supplemented to the date of such letter.

 

o. Market
Activities. The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes
or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of Placement Shares or (ii) sell, bid for, or purchase Common Stock in violation of Regulation M,
or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agents.

 

p. Investment
Company Act. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor the Subsidiaries
will be or become, at any time prior to the termination of this Agreement, an “investment company,” as such term is
defined in the Investment Company Act.

  

    24

    

    

 

q. No
Offer to Sell. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agents in their capacity
as agents hereunder pursuant to Section 23, neither the Agents nor the Company (including its agents and representatives,
other than the Agents in their capacity as such) will make, use, prepare, authorize, approve or refer to any written communication
(as defined in Rule 405), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer
to buy Placement Shares hereunder.

 

r. Sarbanes-Oxley
Act. The Company will maintain and keep accurate books and records reflecting its assets and maintain internal accounting
controls in a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with GAAP and including those policies and procedures that (i) pertain
to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the
assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation
of the Company’s consolidated financial statements in accordance with GAAP, (iii) that receipts and expenditures of the
Company are being made only in accordance with management’s and the Company’s directors’ authorization, and
(iv) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of
the Company’s assets that could have a material effect on its financial statements. The Company will maintain such controls
and other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the
applicable regulations thereunder that are designed to ensure that information required to be disclosed by the Company in the
reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the Commission’s rules and forms, including, without limitation, controls and procedures designed to ensure
that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated
and communicated to the Company’s management, including its principal executive officer and principal financial officer,
or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and to ensure
that material information relating to the Company or the Subsidiaries is made known to them by others within those entities, particularly
during the period in which such periodic reports are being prepared.

 

8. Representations
and Covenants of the Agents. Each of the Agents represents and warrants that it is duly registered as a broker-dealer under
FINRA, the Exchange Act and the applicable statutes and regulations of each state in which the Placement Shares will be offered
and sold, except such states in which such Agent is exempt from registration or such registration is not otherwise required. Each
of the Agents shall continue, for the term of this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange
Act and the applicable statutes and regulations of each state in which the Placement Shares will be offered and sold, except such
states in which such Agent is exempt from registration or such registration is not otherwise required, during the term of this
Agreement. Each of the Agents shall comply with all applicable law and regulations in connection with the transactions contemplated
by this Agreement, including the issuance and sale through the Agents of the Placement Shares.

  

    25

    

    

 

9. Payment
of Expenses. The Company will pay all expenses incident to the performance of its obligations under this Agreement, including
(i) the preparation, filing, including any fees required by the Commission, and printing of the Registration Statement (including
financial statements and exhibits) as originally filed and of each amendment and supplement thereto and each Free Writing Prospectus,
in such number as the Agents shall deem reasonably necessary, (ii) the printing and delivery to the Agents of this Agreement and
such other documents as may be reasonably required in connection with the offering, purchase, sale, issuance or delivery of the
Placement Shares, (iii) the preparation, issuance and delivery of the certificates, if any, for the Placement Shares to the Agents,
including any stock or other transfer taxes and any capital duties, stamp duties or other duties or taxes payable upon the sale,
issuance or delivery of the Placement Shares to the Agents, (iv) the fees and disbursements of the counsel, accountants and other
advisors to the Company, (v) the reasonable fees and disbursements of counsel to the Agents up to a maximum of $25,000; (vi) the
fees and expenses of the transfer agent and registrar for the Common Stock, (vii) the filing fees incident to any review by FINRA
of the terms of the sale of the Placement Shares, and (viii) the fees and expenses incurred in connection with the listing of
the Placement Shares on the Exchange.

 

10. Conditions
to the Agents’ Obligations. The obligations of the Agents hereunder with respect to a Placement will be subject to the
continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance
by the Company of its obligations hereunder, to the completion by the Agents of a due diligence review satisfactory to it in its
reasonable judgment, and to the continuing satisfaction (or waiver by the Agents in their sole discretion) of the following additional
conditions:

 

a. Registration
Statement Effective. The Registration Statement shall have become effective and shall be available for the sale of all Placement
Shares contemplated to be issued by any Placement Notice.

 

b. No
Material Notices. None of the following events shall have occurred and be continuing: (i) receipt by the Company of any request
for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness
of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration
Statement or the Prospectus which have not, as of the time of such Placement, been so made; (ii) the issuance by the Commission
or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement
or the initiation of any proceedings for that purpose; (iii) receipt by the Company of any notification with respect to the suspension
of the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation
or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that requires the making of any changes
in the Registration Statement or the Prospectus so that, in the case of the Registration Statement, it will not contain any materially
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading and, that in the case of the Prospectus, it will not contain any materially untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading, which changes shall not, as of the time of such
Placement, have so been made.

  

    26

    

    

 

c. No
Misstatement or Material Omission. The Agents shall not have advised the Company that the Registration Statement or Prospectus,
or any amendment or supplement thereto, contains an untrue statement of fact that in the Agents’ reasonable opinion is material,
or omits to state a fact that in the Agents’ reasonable opinion is material and is required to be stated therein or is necessary
to make the statements therein not misleading.

 

d. Material
Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission,
there shall not have been any Material Adverse Effect, or any development that could reasonably be expected to cause a Material
Adverse Effect in each case is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement
Shares on the terms and in the manner contemplated in the Prospectus.

 

e. Legal
Opinion. The Agents shall have received the opinions and negative assurances of Company Counsel required to be delivered pursuant
Section 7(m) on or before the date on which such delivery of such opinions are required pursuant to Section 7(m).

 

f. Comfort
Letter. The Agents shall have received the Comfort Letter required to be delivered pursuant Section 7(n) on or before
the date on which such delivery of such letter is required pursuant to Section 7(n).

 

g. Representation
Certificate. The Agents shall have received the certificate required to be delivered pursuant to Section 7(1) on or
before the date on which delivery of such certificate is required pursuant to Section 7(1).

 

h. Secretary’s
Certificate. On or prior to the first Representation Date, the Agents shall have received a certificate, signed on behalf
of the Company by its corporate Secretary, in form and substance reasonably satisfactory to the Agents and their counsel.

 

i. No
Suspension. Trading in the Common Stock shall not have been suspended on the Exchange and the Common Stock shall not have
been delisted from the Exchange.

 

j. Other
Materials. On each date on which the Company is required to deliver a certificate pursuant to Section 7(l), the Company
shall have furnished to the Agents such appropriate further information, certificates and documents as the Agents may reasonably
request. All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof. The Company
will furnish the Agents with such conformed copies of such opinions, certificates, letters and other documents as the Agents shall
reasonably request.

 

k. Securities
Act Filings Made. All filings with the Commission required by Rule 424 under the Securities Act to have been filed prior to
the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing
by Rule 424.

 

l. Approval
for Listing. The Placement Shares shall either have been approved for listing on the Exchange, subject only to notice of issuance,
or the Company shall have filed an application for listing of the Placement Shares on the Exchange at, or prior to, the issuance
of any Placement Notice.

 

m. No
Termination Event. There shall not have occurred any event that would permit the Agents to terminate this Agreement pursuant
to Section 13(a).

  

    27

    

    

 

11. Indemnification
and Contribution.

 

(a) Company
Indemnification. The Company agrees to indemnify and hold

 

harmless
the Agents, their partners, members, directors, officers, employees and agents and each person, if any, who controls the Agents
within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act as follows:

 

(i) against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon
any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment
thereto), or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make
the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included
in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the omission or alleged
omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading;

 

(ii) against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate
amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced
or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement
or omission; provided that (subject to Section 11(d) below) any such settlement is effected with the written consent of
the Company, which consent shall not unreasonably be delayed or withheld; and

 

(iii) against
any and all expense whatsoever, as incurred (including the reasonable documented fees and disbursements of counsel), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above,

 

provided,
however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising
out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity
with written information furnished to the Company by an Agent expressly for use in the Registration Statement (or any amendment
thereto), or in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment thereto).

  

    28

    

    

 

(b) Agent
Indemnification. Each Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company
who signed the Registration Statement, and each person, if any, who (i) controls the Company within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Company against
any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 11(a), as incurred,
but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement
(or any amendments thereto) or in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement
thereto) in reliance upon and in conformity with information relating to such Agent and furnished to the Company in writing by
such Agent expressly for use therein.

 

(c) Procedure.
Any party that proposes to assert the right to be indemnified under this Section 11 will, promptly after receipt of
notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party
or parties under this Section 11, notify each such indemnifying party of the commencement of such action, enclosing a copy
of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any
liability that it might have to any indemnified party otherwise than under this Section 11 and (ii) any liability that
it may have to any indemnified party under the foregoing provision of this Section 11 unless, and only to the extent that,
such omission results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought
against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled
to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after receiving
notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified,
to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the
indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to
the indemnified party for any legal or other expenses except as provided below and except for the reasonable costs of investigation
subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ
its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified
party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party,
(2) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to
it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict
or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying
party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified
party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action within a reasonable
time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements and other
charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or
parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable
fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one time
for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying
party promptly after the indemnifying party receives a written invoice relating to fees, disbursements and other charges in reasonable
detail. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its
written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise
or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated
by this Section 11 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent
(1) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation,
proceeding or claim and (2) does not include a statement as to or an admission of fault, culpability or a failure to act by or
on behalf of any indemnified party.

  

    29

    

    

 

(d) Contribution.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the
foregoing paragraphs of this Section 11 is applicable in accordance with its terms but for any reason is held to be unavailable
from the Company or an Agent, the Company and such Agent will contribute to the total losses, claims, liabilities, expenses and
damages (including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in
settlement of, any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company
from persons other than the Agents, such as persons who control the Company within the meaning of the Securities Act or the Exchange
Act, officers of the Company who signed the Registration Statement and directors of the Company, who also may be liable for contribution)
to which the Company and the Agents may be subject in such proportion as shall be appropriate to reflect the relative benefits
received by the Company on the one hand and the Agents on the other hand. The relative benefits received by the Company on the
one hand and the Agents on the other hand shall be deemed to be in the same proportion as the total Net Proceeds from the sale
of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by the Agents
(before deducting expenses) from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided
by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion
as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault
of the Company, on the one hand, and such Agent, on the other hand, with respect to the statements or omission that resulted in
such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations
with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue
or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or such Agent, the intent of the parties and their relative knowledge, access to information and opportunity
to correct or prevent such statement or omission. The Company and each Agent agree that it would not be just and equitable if
contributions pursuant to this Section 11(d) were to be determined by pro rata allocation or by any other method of allocation
that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified
party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this Section
11(d) shall be deemed to include, for the purpose of this Section 11(d), any legal or other expenses reasonably incurred
by such indemnified party in connection with investigating or defending any such action or claim to the extent consistent with
Section 11(c) hereof. Notwithstanding the foregoing provisions of this Section 11(d), and except in the case of
gross negligence or willful misconduct, an Agent shall not be required to contribute any amount in excess of the commissions received
by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
For purposes of this Section 11(d), any person who controls a party to this Agreement within the meaning of the Securities
Act or the Exchange Act, and any officers, directors, partners, employees or agents of an Agent, will have the same rights to
contribution as that party, and each officer and director of the Company who signed the Registration Statement will have the same
rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly
after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be made
under this Section 11(d), will notify any such party or parties from whom contribution may be sought, but the omission
to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they
may have under this Section 11(d) except to the extent that the failure to so notify such other party materially prejudiced
the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant
to the last sentence of Section 11(c) hereof, no party will be liable for contribution with respect to any action or claim
settled without its written consent if such consent is required pursuant to Section 11(c) hereof.

  

    30

    

    

 

12. Representations
and Agreements to Survive Delivery. The indemnity and contribution agreements contained in Section 11 of this Agreement and
all representations and warranties of the Company and the Agents herein or in certificates delivered pursuant hereto shall survive,
as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agents, any controlling persons,
or the Company (or any of their respective officers, directors or controlling persons), (ii) delivery and acceptance of the Placement
Shares and payment therefor or (iii) any termination of this Agreement.

 

13. Termination.

 

a. An
Agent may terminate this Agreement, written by notice to the Company, as hereinafter specified at any time (1) if there has been,
since the time of execution of this Agreement or since the date as of which information is given in the Prospectus, any Material
Adverse Effect, or any development that is reasonably likely to have a Material Adverse Effect or, in the reasonable judgment
of such Agent, is material and adverse and makes it impractical or inadvisable to market the Placement Shares or to enforce contracts
for the sale of the Placement Shares, (2) if there has occurred any material adverse change in the financial markets in the United
States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or
any change or development involving a prospective change in national or international political, financial or economic conditions,
in each case the effect of which is such as to make it, in the reasonable and good faith judgment of such Agent, impracticable
or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares, (3) if trading in
the Common Stock has been suspended or limited by the Commission or the Exchange, or if trading generally on the Exchange has
been suspended or limited, or minimum prices for trading have been fixed on the Exchange, (4) if any suspension of trading of
any securities of the Company on any exchange or in the over-the-counter market shall have occurred and be continuing for a period
of at least 10 days, (5) if a major disruption of securities settlements or clearance services in the United States shall have
occurred and be continuing, or (6) if a banking moratorium has been declared by either U.S. Federal or New York authorities. Any
such termination shall be without liability of any party to any other party except that the provisions of Section 9 (Payment
of Expenses), Section 11 (Indemnification and Contribution), Section 12 (Representations and Agreements to Survive
Delivery), Section 18 (Governing Law and Time; Waiver of Jury Trial) and Section 19 (Consent to Jurisdiction) hereof
shall remain in full force and effect notwithstanding such termination. If an Agent elects to terminate this Agreement as provided
in this Section 13(a), such Agent shall provide the required notice as specified in Section 14 (Notices).

  

    31

    

    

 

b. The
Company shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole
discretion (for any reason or no reason) at any time after the date of this Agreement. Any such termination shall be without liability
of any party to any other party except that the provisions of Section 9 (Payment of Expenses), Section 11 (Indemnification
and Contribution), Section 12 (Representations and Agreements to Survive Delivery), Section 18 (Governing Law and
Time; Waiver of Jury Trial) and Section 19 (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding
such termination.

 

c. Each
Agent shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole discretion
(for any reason or no reason) at any time after the date of this Agreement. Any such termination shall be without liability of
any party to any other party except that the provisions of Section 9 (Payment of Expenses), Section 11 (Indemnification
and Contribution), Section 12 (Representations and Agreements to Survive Delivery), Section 18 (Governing Law and
Time; Waiver of Jury Trial) and Section 19 (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding
such termination.

 

d. Unless
earlier terminated pursuant to this Section 13, this Agreement shall automatically terminate upon the issuance and sale
of all of the Placement Shares through the Agents on the terms and subject to the conditions set forth herein except that the
provisions of Section 9 (Payment of Expenses), Section 11 (Indemnification and Contribution), Section 12
(Representations and Agreements to Survive Delivery), Section 18 (Governing Law and Time; Waiver of Jury Trial) and Section
19 (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding such termination.

 

e. This
Agreement shall remain in full force and effect unless terminated pursuant to Sections 13(a), (b), (c), or
(d) above or otherwise by mutual agreement of the parties; provided, however, that any such termination by mutual
agreement shall in all cases be deemed to provide that Section 9 (Payment of Expenses), Section 11 (Indemnification
and Contribution), Section 12 (Representations and Agreements to Survive Delivery), Section 18 (Governing Law and
Time; Waiver of Jury Trial) and Section 19 (Consent to Jurisdiction) shall remain in full force and effect. Upon termination
of this Agreement, the Company shall not have any liability to an Agent for any discount, commission or other compensation with
respect to any Placement Shares not otherwise sold by an Agent under this Agreement.

 

f. Any
termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however,
that such termination shall not be effective until the close of business on the date of receipt of such notice by an Agent or
the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares,
such Placement Shares shall settle in accordance with the provisions of this Agreement.

  

    32

    

    

 

14.
Notices. All notices or other communications required or permitted to be given by any party to any other party pursuant
to the terms of this Agreement shall be in writing, unless otherwise specified, and if sent to the Agents, shall be delivered
to:

  

B.
Riley FBR, Inc.

299
Park Avenue

New
York, NY 10171

Attention: General
Counsel

Telephone:     (212) 457-9947

Email:  atmdesk@brileyfbr.com

  

And

  

JonesTrading
Institutional Services LLC

900
Island Park Drive, Suite 160

Daniel
Island, SC 29492

Attention:      Burke
Cook

Email:  Burke@jonestrading.com

 

with
a copy to:

 

Duane
Morris LLP

1540
Broadway

New
York, NY 10036

Attention:      James
T. Seery

Telephone:    (973)
424-2088

Email:  jtseery@duanemorris.com

 

and
if to the Company, shall be delivered to:

 

Actinium
Pharmaceuticals, Inc.

275
Madison Avenue, 7th Floor

New
York, NY 10016

Attention:      Chief Executive Officer

Telephone:    (646) 677-3870

Email:  sseth@actiniumpharma.com

 

with
a copy to:

 

The
Matt Law Firm, PLLC

1701
Genesee Street

Utica,
New York 13501

Attention:      Thomas Slusarczyk, Esq.

Telephone:    (315) 235-2299

Email:  tslusarczyk@mattlawfirm.com

 

    33

    

    

 

Each
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new
address for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally, by email,
or by verifiable facsimile transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business
Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii) on the next Business Day after timely delivery
to a nationally-recognized overnight courier and (iii) on the Business Day actually received if deposited in the U.S. mail (certified
or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, “Business Day”
shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.

 

An
electronic communication (“Electronic Notice”) shall be deemed written notice for purposes of this Section
14 if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be
deemed received at the time the party sending Electronic Notice receives confirmation of receipt by the receiving party. Any party
receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (“Nonelectronic
Notice”) which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic
Notice.

 

15. Successors
and Assigns. This Agreement shall inure to the benefit of and be binding upon the Company and each Agent and their respective
successors and the affiliates, controlling persons, officers and directors referred to in Section 11 hereof. References
to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party.
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except
as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior
written consent of the other party.

 

16. Adjustments
for Stock Splits. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted
to take into account any share consolidation, stock split, stock dividend, corporate domestication or similar event effected with
respect to the Placement Shares.

 

17. Entire
Agreement; Amendment; Severability. This Agreement (including all schedules and exhibits attached hereto and Placement Notices
issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,
both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term
hereof may be amended except pursuant to a written instrument executed by the Company and the Agents. In the event that any one
or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable
as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible
extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if
such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to
such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected
in this Agreement.

 

    34

    

    

 

18. GOVERNING
LAW AND TIME; WAIVER OF JURY TRIAL. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE
OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY
HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

19. CONSENT
TO JURISDICTION. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION
CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT
IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT
FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE
OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR
REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES
THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE
DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.

 

20. Use
of Information. The Agents may not use any information gained in connection with this Agreement and the transactions contemplated
by this Agreement, including due diligence, to advise any party with respect to transactions not expressly approved by the Company.

 

21. Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile
transmission.

 

22. Effect
of Headings. The section and Exhibit headings herein are for convenience only and shall not affect the construction hereof.

 

    35

    

    

 

23. Permitted
Free Writing Prospectuses.

 

The
Company represents, warrants and agrees that, unless it obtains the prior consent of each Agent, which consent shall not be unreasonably
withheld, conditioned or delayed, and each Agent represents, warrants and agrees that, unless it obtains the prior consent of
the Company, which consent shall not be unreasonably withheld, conditioned or delayed, it has not made and will not make any offer
relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute a
“free writing prospectus,” as defined in Rule 405, required to be filed with the Commission. Any such free writing
prospectus consented to by the Agents or by the Company, as the case may be, is hereinafter referred to as a “Permitted
Free Writing Prospectus.” The Company represents and warrants that it has treated and agrees that it will treat each Permitted
Free Writing Prospectus as an “issuer free writing prospectus,” as defined in Rule 433, and has complied and will
comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the
Commission where required, legending and record keeping. For the purposes of clarity, the parties hereto agree that all free writing
prospectuses, if any, listed in Exhibit 23 hereto are Permitted Free Writing Prospectuses.

 

24.
Absence of Fiduciary Relationship. The Company acknowledges and agrees that:

 

a. Each
Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction
contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between
the Company or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party,
on the one hand, and the Agents, on the other hand, has been or will be created in respect of any of the transactions contemplated
by this Agreement, irrespective of whether or not any Agent has advised or is advising the Company on other matters, and the Agents
have no obligation to the Company with respect to the transactions contemplated by this Agreement except the obligations expressly
set forth in this Agreement;

 

b. it
is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;

 

c. the
Agents have not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this
Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;

 

d. it
is aware that the Agents and their affiliates are engaged in a broad range of transactions which may involve interests that differ
from those of the Company and such Agent has no obligation to disclose such interests and transactions to the Company by virtue
of any fiduciary, advisory or agency relationship or otherwise; and

 

e. it
waives, to the fullest extent permitted by law, any claims it may have against the Agents for breach of fiduciary duty or alleged
breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that the Agents shall
not have any liability (whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty
claim or to any person asserting a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors
of Company, other than in respect of the Agents’ obligations under this Agreement and to keep information provided by the
Company to the Agents and the Agents’ counsel confidential to the extent not otherwise publicly-available.

  

    36

    

    

 

25. Definitions.

 

As
used in this Agreement, the following terms have the respective meanings set forth below:

  

“Applicable
Time” means (i) each Representation Date and (ii) the time of each sale of any Placement Shares pursuant to this Agreement.

 

“Issuer
Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433, relating to
the Placement Shares that (1) is required to be filed with the Commission by the Company, (2) is a “road show” that
is a “written communication” within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the
Commission, or (3) is exempt from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares
or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission
or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities
Act.

 

“Rule
172,” “Rule 405,” “Rule 415,” “Rule 424,” “Rule 424(b),”
“Rule 430B,” and “Rule 433” refer to such rules under the Securities Act.

 

All
references in this Agreement to financial statements and schedules and other information that is “contained,” “included”
or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed
to mean and include all such financial statements and schedules and other information that is incorporated by reference in the
Registration Statement or the Prospectus, as the case may be.

 

All
references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing
shall be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer
Free Writing Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed
with the Commission) shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references
in this Agreement to “supplements” to the Prospectus shall include, without limitation, any supplements, “wrappers”
or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agents
outside of the United States.

 

[Remainder
of the page intentionally left blank]

 

    37

    

    

 

If
the foregoing correctly sets forth the understanding between the Company and each of the Agents, please so indicate in the space
provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and each of the
Agents.

 

	 	Very truly yours,
	 	 
	 	ACTINIUM PHARMACEUTICALS, INC.
	 	 
	 	By:	/s/ Sandesh Seth
	 	 	Name:	 Sandesh Seth
	 	 	Title:	Chairman of the Board and CEO
	 	 
	 	ACCEPTED as of the date first-above written:
	 	B. RILEY FBR, INC.
	 	 
	 	By:	/s/ Patrice McNicoll
	 	 	Name:	Patrice McNicoll
	 	 	Title:	Co-Head of Investment Banking
	 	 
	 	JONESTRADING INSTITUTIONAL

 SERVICES LLC
	 	 
	 	By:	/s/ Burke Cook
	 	 	Name:	Burke Cook
	 	 	Title:	General Counsel

 

     

    

    

 

SCHEDULE
1

 

 

 

FORM
OF PLACEMENT NOTICE

 

 

 

		From:	Actinium
Pharmaceuticals, Inc.

 

		To:	[●]

 

		Attention:	[●]

 

		Subject:	At
Market Issuance--Placement Notice

 

Gentlemen:

 

Pursuant
to the terms and subject to the conditions contained in the Amended and Restated At Market Issuance Sales Agreement between Actinium
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and B. Riley FBR, Inc. and JonesTrading Institutional
Services LLC (the “Agents”), dated December [28], 2018, the Company hereby requests that [Identify Designated
Agent] sell up to [_______] shares of the Company’s Common Stock, $0.001 par value per share, at a minimum market price
of $ per share, during the time period beginning [month, day, time] and ending [month, day, time].

 

     

    

    

 

SCHEDULE
2

 

 

 

Compensation

 

 

 

The
Company shall pay to the Designated Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal
to 3.0% of the gross proceeds from each sale of Placement Shares.

 

     

    

    

 

SCHEDULE
3

 

 

 

 

Notice
Parties

 

 

 

 

	The Company	 
	 	 
	Sandesh Seth	sseth@actiniumpharma.com
	Steve O’Loughlin	soloughlin@actiniumpharma.com
	 	 
	B. Riley FBR	 
	 	 
	Matthew Feinberg	mfeinberg@brileyfbr.com
	Ryan Loforte	rloforte@brileyfbr.com
	Patrice McNicoll	pmcnicoll@brileyfbr.com  
	Keith Pompliano	kpompliano@brileyfbr.com
	 	 
	with a copy to atmdesk@brileyfbr.com	 
	 	 
	JonesTrading	 
	 	 
	Moe Cohen	moec@jonestrading.com  
	Bryan Turley	bturley@jonestrading.com  
	John D’Agostini	johnd@jonestrading.com  
	Ryan Gerety	ryang@jonestrading.com  
	 	 
	With
a copy to JTCM@jonestrading.com	 

 

     

    

    

 

SCHEDULE 6(g)

 

 

 

 

Subsidiaries

 

 

 

MedActinium,
Inc.

 

     

    

    

 

EXHIBIT
7(1)

Form of Representation Date Certificate 

 

____________________,
20___

 

This
Representation Date Certificate (this “Certificate”) is executed and delivered in connection with Section
7(1) of the Amended and Restated At Market Issuance Sales Agreement (the “Agreement”), dated December 28,
2018, and entered into between Actinium Pharmaceuticals, Inc. (the “Company”) and B. Riley FBR, Inc. and JonesTrading
Institutional Services LLC. All capitalized terms used but not defined herein shall have the meanings given to such terms in the
Agreement.

 

The
Company hereby certifies as follows:

 

1. As
of the date of this Certificate (i) the Registration Statement does not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading and
(ii) neither the Registration Statement nor the Prospectus contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading and (iii) no event has occurred as a result of which it is necessary to amend or supplement
the Prospectus in order to make the statements therein not untrue or misleading for this paragraph 1 to be true.

 

2. Each
of the representations and warranties of the Company contained in the Agreement were, when originally made, and are, as of the
date of this Certificate, true and correct in all material respects.

 

3. Except
as waived by the Agents in writing, each of the covenants required to be performed by the Company in the Agreement on or prior
to the date of the Agreement, this Representation Date, and each such other date prior to the date hereof as set forth in the
Agreement, has been duly, timely and fully performed in all material respects and each condition required to be complied with
by the Company on or prior to the date of the Agreement, this Representation Date, and each such other date prior to the date
hereof as set forth in the Agreement has been duly, timely and fully complied with in all material respects.

 

4. Subsequent
to the date of the most recent financial statements in the Prospectus, and except as described in the Prospectus, including Incorporated
Documents, there has been no Material Adverse Effect.

 

5. No
stop order suspending the effectiveness of the Registration Statement or of any part thereof has been issued, and no proceedings
for that purpose have been instituted or are pending or threatened by any securities or other governmental authority (including,
without limitation, the Commission).

 

6. No
order suspending the effectiveness of the Registration Statement or the qualification or registration of the Placement Shares
under the securities or Blue Sky laws of any

 

     

    

    

  

jurisdiction
are in effect and no proceeding for such purpose is pending before, or threatened, to the Company’s knowledge or in writing
by, any securities or other governmental authority (including, without limitation, the Commission).

 

The
undersigned has executed this Representation Date Certificate as of the date first written above.

 

	 	ACTINIUM PHARMACEUTICALS, INC.
	 	 
	 	By:	                            
	 	Name: 	 
	 	Title:	 

  

     

    

    

 

EXHIBIT
23

 

Permitted
Issuer Free Writing Prospectuses

 

None.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]